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SUMMARY
IL-2 plays a critical role in the induction and maintenance of FoxP3-expressing regulatory T cells
(FoxP3+Treg). Reduced expression of IL-2 is linked to T cell-mediated autoimmune diseases such
as Type 1 diabetes (T1D), in which an imbalance between FoxP3+Treg and pathogenic T effectors
exists. We investigated the contribution of IL-2 to dysregulation of FoxP3+Treg by comparing
wildtype NOD mice with animals congenic for a C57BL/6-derived disease resistant Il2 allele and
in which T cell secretion of IL-2 is increased (NOD.B6Idd3). Whereas NOD mice exhibited a
progressive decline in the frequency of CD62LHIFoxP3+Treg due to an increase in
CD62LLOFoxP3+Treg, CD62LHIFoxP3+Treg were maintained in the pancreatic lymph nodes and
islets of NOD.B6Idd3 mice. Notably, the frequency of proliferating CD62LHIFoxP3+Treg was
elevated in the islets of NOD.B6Idd3 versus NOD mice. Increasing levels of IL-2 in vivo also
resulted in larger numbers of CD62LHIFoxP3+Treg in NOD mice. These results demonstrate that
IL-2 influences the suppressor activity of the FoxP3+Treg pool by regulating the balance between
CD62LLO and CD62LHI FoxP3+Treg. In NOD mice reduced IL-2 expression leads to an increase
in nonsuppressive CD62LLOFoxP3+Treg, which in turn correlates with a pool of
CD62LHIFoxP3+Treg with limited proliferation.
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INTRODUCTION
The hallmark of Type 1 diabetes (T1D) is the T cell-mediated destruction of the insulin-
producing β cells in the pancreatic islets [1-3]. Based on studies in humans and the NOD
mouse, a spontaneous model of T1D, the breakdown of β cell-specific tolerance is in part
due to defective peripheral immunoregulation within the T cell compartment. Conventional
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T cells in NOD mice for instance, exhibit reduced sensitivity to the suppressive effects of
immunoregulatory T cells (Treg) [4, 5]. The loss of function and/or frequency of Treg has
also been implicated in the differentiation and expansion of pathogenic type 1 effector T
cells specific for β cells [5-7]. Several subsets of Treg with distinct phenotypes and effector
functions have been identified [8] including: i) type 2 T effectors which predominantly
secrete IL-4, ii) Th3 cells, which primarily secrete IL-4 and TGFβ [9], iii) IL-10 secreting
Treg [10], and iv) natural and adaptive CD4+CD25+ T cells which express the transcription
factor Forkhead box P3 (FoxP3+Treg) [11].
FoxP3+Treg are considered to be the most potent subset of Treg, and are characterized by a
suppressor function mediated by cell-cell contact-dependent and -independent mechanisms
[12]. Humans and mice lacking functional FoxP3 protein develop systemic T cell-mediated
autoimmunity [13-15]. FoxP3+Treg suppress T cells through constitutive expression of
CTLA-4 and the glucocorticoid-induced TNF receptor (GITR) which block co-stimulatory
signals needed for T cell activation [16]. Additionally, FoxP3+Treg elicit suppression
through a bystander effect via TGFβ [12, 17], which modulates the function of APC and
inhibits production of IFNγ and TNFα by type 1 T effectors [18].
The phenotype of FoxP3+Treg can be further defined based on CD62L expression. For
instance, the in vitro and/or in vivo suppressor function of CD62LHIFoxP3+Treg is superior
compared to CD62LLOFoxP3+Treg [7, 19, 20]. Furthermore, CD62LHIFoxP3+Treg from the
pancreatic lymph nodes (PLN) or spleen of NOD mice exhibit an enhanced capacity to
prevent diabetes in an adoptive transfer model compared to CD62LLOFoxP3+Treg [19].
Increased levels of TGFβ expression contributes to the enhanced suppressor function of
CD62LHIFoxP3+Treg versus CD62LLOFoxP3+Treg [7]. CD62LLOFoxP3+Treg are thought
to reflect an activated phenotype characterized by increased cycling [21-23]. Importantly,
our group and others have previously shown that the frequency of suppressive
CD62LHIFoxP3+Treg decline with age in NOD female mice which corresponds with the
progression of β cell autoimmunity [7, 24]. The critical events that induce and maintain the
frequency of CD62LHIFoxP3+Treg, however, are poorly understood.
Recent studies have demonstrated that IL-2 plays a key role in the maintenance of
FoxP3+Treg homeostasis [25, 26]. Mice lacking or having reduced expression of the Il2
gene develop severe, systemic autoimmunity due to the reduction of FoxP3+Treg [27, 28].
Furthermore, Sakaguchi et al. showed that diabetes is exacerbated in NOD mice when
treated with a neutralizing Ab specific for IL-2 at an early age [29]. Also, IL-2 in
combination with TGFβ is important for the differentiation of naïve CD4+ T cells into
adaptive FoxP3+Treg in vitro [30, 31].
More than 20 chromosomal loci, termed insulin-dependent diabetes (Idd) regions, are
associated with T1D susceptibility and resistance [32, 33]. While no one gene is sufficient
for the development of diabetes, the combined effects of susceptibility genes influence the
progression of β cell autoimmunity [32, 33]. NOD mice congenic for the Idd3 locus derived
from diabetes-resistant mouse strains exhibit a reduced incidence and delayed onset of T1D
[34-37]. Idd3 contains genes encoding immunoregulatory molecules including IL-2 and
IL-21 [34-37]. The NOD Idd3 locus has been associated with reduced IL-2 expression by T
cells and an aberrant FoxP3+Treg pool [37, 38]. These findings suggest that T1D is
influenced by dysregulation of IL-2 expression, which leads to reduced FoxP3+Treg
frequency and/or function found in NOD mice. In the current study, NOD mice congenic for
a resistant Idd3 interval derived from C57BL/6 (B6) mice (NOD.B6Idd3) were used to
further define the role of IL-2 in regulating the peripheral FoxP3+Treg pool. We present
evidence that reduced IL-2 expression leads to temporal dysregulation of the ratio between
suppressor-deficient CD62LLOFoxP3+Treg and suppressor-competent
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CD62LHIFoxP3+Treg, resulting in a pool of FoxP3+Treg insufficient to regulate β cell
autoimmunity.
RESULTS
An age-dependent decline in CD62LHIFoxP3+Treg is detected in NOD but not NOD.B6Idd3
mice
Studies have demonstrated that Idd3 in NOD mice contributes to the progression of β cell
autoimmunity by influencing the pool of FoxP3+Treg [37, 38]. To further study the effect(s)
of Idd3 on FoxP3+Treg, NOD.B6Idd3 mice congenic for an ~17 Mb interval derived from
the B6 genotype were employed (Supplementary Table 1). This line of NOD.B6Idd3 female
mice exhibited a reduced frequency of diabetes and insulitis relative to NOD female mice
(Fig. 1), similar to other NOD mouse lines congenic for a resistant Idd3 locus [37-39].
Consistent with previous findings [38] naïve CD4+ T cells isolated from the spleen of
NOD.B6Idd3 mice exhibited increased IL-2 secretion upon in vitro stimulation relative to
NOD CD4+ T cells (Supplementary Fig. 1). To determine the influence of Idd3 on
FoxP3+Treg, the frequency and number of gated CD4+CD3+ T cells expressing FoxP3 and
CD25 (Fig. 2A) were assessed in the thymus, spleen, PLN and islets of age-matched NOD
and NOD.B6Idd3 female mice via FACS. No difference in the frequency of FoxP3+Treg
was detected in the thymus of NOD and NOD.B6Idd3 mice suggesting that thymic
development of FoxP3+Treg is unaffected by IL-2 expression levels. On the other hand, an
increased frequency and number of FoxP3+Treg was detected in the PLN and spleen of
older NOD.B6Idd3 mice relative to age-matched NOD mice (Fig. 2A-C). In addition, the
frequency of FoxP3+Treg was significantly increased in the islets of 10 and 16 wk-old
NOD.B6Idd3 versus NOD female mice (Fig. 2B). Notably, however, a greater number of
FoxP3+Treg was detected in the islets of older NOD mice (Fig. 2C) reflecting increased T
cell infiltration of the islets relative to age-matched NOD.B6Idd3 mice. These data
demonstrate that the frequency of FoxP3+Treg is increased in the PLN and islets of
NOD.B6Idd3 mice compared to NOD mice.
We and others have shown that CD62LHI- versus CD62LLO-expressing FoxP3+Treg exhibit
increased suppressor activity [7, 19]. Accordingly, CD62LHI- and CD62LLO-expressing
FoxP3+Treg were examined temporally in age-matched NOD.B6Idd3 and NOD female
mice. Interestingly, age-dependent differences in the frequency and number of CD62LHI-
and CD62LLO-expressing FoxP3+Treg were detected in the PLN and islets of the respective
groups of mice. NOD female mice exhibited a temporal decrease in the frequency of
CD62LHIFoxP3+Treg and a concomitant increase in CD62LLOFoxP3+Treg in PLN (Fig.
3B). Although the number of CD62LHIFoxP3+Treg progressively increased in the PLN of
NOD female mice (5.2 ×104 (4 wks) versus 9.0×104 (16 wks)), a greater increase in
CD62LLOFoxP3+Treg numbers was detected (6.3×104 (4 wks) versus 14.9×104 (16 wks))
(Fig. 3C). In the PLN of NOD.B6Idd3 mice, however, the frequency and number of
CD62LHIFoxP3+Treg showed no marked change with age, which were increased relative to
age-matched NOD females (Fig. 3B,C).
A similar scenario was observed in the islets of NOD and NOD.B6Idd3 female mice. A
temporal increase in the frequency of CD62LLOFoxP3+Treg was detected in the islets of
NOD female mice which was due to elevated numbers relative to CD62LHIFoxP3+Treg
(Fig. 3D,E). Despite a progressive decline, the frequency of CD62LHIFoxP3+Treg in the
islets of NOD.B6Idd3 female mice was elevated relative to age-matched NOD female mice
(Fig. 3D,E). FACS analysis showed similar levels of CD25, GITR and CTLA-4 surface
expression between CD62LHIFoxP3+Treg and CD62LLOFoxP3+Treg infiltrating the islets
of either NOD or NOD.B6Idd3 mice (data not shown).
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Differences in the proliferative status of CD62LHI- versus CD62LLO-expressing
FoxP3+Treg could explain the distinct FoxP3+Treg profiles seen in the islets of NOD and
NOD.B6Idd3 mice. To investigate this possibility, proliferation of
CD62LHICD4+CD25+FoxP3+ and CD62LLOCD4+CD25+FoxP3+ T cells was assessed via
Ki67 staining in the islets of 12 wk-old NOD and NOD.B6Idd3 female mice. Regardless of
the genotype, the frequency of proliferating CD62LLOCD4+CD25+FoxP3+ T cells was
elevated relative to CD62LHICD4+CD25+FoxP3+ T cells (Fig. 4B). Importantly, however,
the frequency of proliferating CD62LHICD4+CD25+FoxP3+ T cells (Fig. 4B) and the ratio
of Ki67-staining CD62LHICD4+CD25+FoxP3+ to CD62LLOCD4+CD25+FoxP3+ T cells
(Fig. 4C) were increased in the islets of NOD.B6Idd3 versus NOD female mice. Together,
these results indicate that within the pool of FoxP3+Treg a significant shift from
CD62LHIFoxP3+Treg to CD62LLOFoxP3+Treg occurs in the PLN and islets of NOD but to
a lesser extent in NOD.B6Idd3 female mice, which correlates with a decreased proliferative
status of CD62LHIFoxP3+Treg in NOD versus NOD.B6Idd3 mice.
Increased CD62LHIFoxP3+Treg enhance the suppressor activity of the pool of FoxP3+Treg
from NOD.B6Idd3 versus NOD mice
Elevated numbers of CD62LHIFoxP3+Treg in NOD.B6Idd3 mice would be expected to
enhance suppression of pathogenic T effectors in the respective tissues. Indeed, at 16 wks of
age the frequency of insulitis is reduced in 16 wk-old NOD.B6Idd3 versus NOD female
mice (Fig. 1B). Consistent with the latter the ratio of CD62LHIFoxP3+Treg versus IFNγ-
secreting CD4+ T cells in the islets and PLN was significantly increased in 16 wkold
NOD.B6Idd3 versus NOD female mice (Fig. 5A). The overall frequency of proliferating T
cells was reduced in the islets of 16 wk-old NOD.B6Idd3 versus NOD female mice (Fig.
5B). To directly assess the in vivo suppressor activity of NOD and NOD.B6Idd3
FoxP3+Treg, co-adoptive transfer experiments were carried out. CD4+CD25+ T cells were
prepared from PLN of 16 wk-old NOD.B6Idd3 or NOD female mice, co-injected with
splenocytes from diabetic NOD donors into NOD.scid mice, and diabetes monitored.
Importantly, the frequency of FoxP3-expressing cells in the pool of sorted CD4+CD25+ T
cells was similar between NOD and NOD.B6Idd3 donors (72±5% and 75±3, respectively;
average of 3 separate experiments). As expected all NOD.scid mice receiving diabetogenic
splenocytes-alone developed diabetes (Fig. 5C). Similarly, the entire group of NOD.scid
mice injected with a mixture of diabetogenic splenocytes plus NOD CD4+CD25+ T cells
developed diabetes albeit with delayed kinetics (Fig. 5C). In contrast, NOD.scid mice
receiving NOD.B6Idd3 CD4+CD25+ T cells plus diabetogenic splenocytes exhibited a
significantly delayed onset and reduced frequency of diabetes relative to recipients of the
cell mixture containing NOD CD4+CD25+ T cells (Fig. 5C). Therefore CD4+CD25+ T cells
from NOD.B6Idd3 mice exhibit an increased suppressor activity compared to NOD
CD4+CD25+ T cells.
To determine whether the protection mediated by NOD.B6Idd3 CD4+CD25+ T cells was
due to quantitative or qualitative differences within the pool of CD62LHIFoxP3+Treg, the
suppressor activity of these immunoregulatory effectors was tested in vitro. CD62LLO- and
CD62LHI-expressing CD4+CD25+ T cells were FACS sorted from the PLN of 16 wkold
NOD.B6Idd3 and NOD female mice, and then cultured at various ratios with naïve CD4+ T
cells from the spleen of NOD mice. As expected, CD62LLOCD4+CD25+ T cells from either
NOD.B6Idd3 or NOD female mice were inefficient at suppressing proliferation of the
stimulated CD4+ T cells (Fig. 5D). On the other hand, CD62LHICD4+CD25+ T cells
effectively suppressed proliferation of the responder CD4+ T cells. Furthermore, no
significant difference in suppressor activity of NOD.B6Idd3 and NOD
CD62LHIFoxP3+Treg was detected (Fig. 5D). Therefore, the enhanced suppressor activity
detected in the PLN of NOD.B6Idd3 mice is due to an increased number of
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CD62LHIFoxP3+Treg, consistent with results obtained in the above co-adaptive transfer
experiments (Fig. 5C).
The frequency of CD62LHIFoxP3+Treg is increased in vivo in NOD mice treated with IL-2
Since IL-2 secretion by conventional T cells is limited in NOD mice compared to
NOD.B6Idd3 animals (Supplementary Figure 1) [38], then increasing the level of
“endogenous” IL-2 would be expected to enhance the frequency of CD62LHIFoxP3+Treg in
vivo. To test this hypothesis 10 wk-old NOD female mice were injected intramuscularly
with a doxycycline inducible AAV recombinant encoding IL-2 (AAVTet-IL-2). No
difference was detected in the frequency of CD4+CD25+Foxp3+ T cells in AAV-Tet-IL-2
treated but uninduced NOD mice or animals left untreated (Fig. 6A,B). In contrast, NOD
mice treated with AAV-Tet-IL-2 and in which IL-2 transgene expression was induced
exhibited an increased frequency of CD4+CD25+Foxp3+ in all tissues tested (Fig. 6A,B),
and showed a significant increase in CD62LHI-expressing CD4+CD25+Foxp3+ T cells in the
PLN (Fig. 6C). Furthermore, addition of IL-2 to FACS-sorted CD62LLO-expressing
CD4+CD25+ T cells up-regulated expression of CD62L in vitro (Fig. 6D). These results
indicate that: 1) IL-2 availability in vivo regulates the frequency of CD62LHIFoxP3+Treg,
and 2) IL-2 can “convert” CD62LLOFoxP3+Treg into CD62LHIFoxP3+Treg in vitro.
DISCUSSION
Analyses of NOD mice congenic for protective Idd3 intervals have shown that aberrant
expression of IL-21 and IL-2 influences various aspects of β cell autoimmunity in NOD
mice [34-38]. Increased expression of IL-21 and IL-21R by T cells is associated with
enhanced development of pathogenic T effectors in NOD mice through for instance,
disruption of T cell homeostasis [34, 36, 40-42]. IL-21 has also been reported to render
conventional T cells resistant to the suppressor effects of FoxP3+Treg [43, 44]. In NOD
mice the resistance of conventional T cells to Treg-mediated suppression, however, appears
to be independent of Idd3 [45]. On the other hand, decreased transcription of the Il2 gene in
NOD mice has been linked to a reduced frequency of FoxP3+Treg in the PLN, decreased
intra-islet survival, a limited suppressor function of FoxP3+Treg, in addition to an impaired
capacity of FoxP3+Treg to expand in the islets [24, 37, 38]. Differences in glycosylation of
IL-2 between B6 and NOD mice, however, have no effect on diabetes development [46].
The current study provides new insight into how dysregulation of IL-2 adversely influences
the pool of FoxP3+Treg in NOD mice as T1D progresses. We show that reduced IL-2
expression in NOD mice is associated with a temporal shift favoring CD62LLO- versus
CD62LHI-expressing FoxP3+Treg (Fig. 3) thereby altering the composition and diminishing
the suppressor function of the overall pool of FoxP3+Treg (Fig. 5).
Previous work by our group [7] and others [38] demonstrated that the progression of β cell
autoimmunity correlates with an age-dependent decrease in the frequency of
CD62LHIFoxP3+Treg in NOD female mice. The current study shows that this decrease is
due to an inverse relationship between CD62LHI- and CD62LLO-expressing FoxP3+Treg
that is dependent on the level of IL-2 expression. A direct role for IL-2 in regulating the
balance between CD62LHIFoxP3+Treg and CD62LLOFoxP3+Treg was seen in vitro and in
vivo. Supplementing cultures of sorted CD62LLOCD4+CD25+ T cells with IL-2 for
instance, increased the frequency of CD62LHICD4+CD25+ T cells (Fig. 6D). In addition, an
increase in the frequency of CD62LHIFoxP3+Treg was detected in the PLN of NOD mice
following a brief induction of AAV encoded IL-2 (Fig. 6C). This in vivo pulse of ectopic
IL-2 also resulted in effective suppression of β cell autoimmunity and prevention of overt
diabetes in treated NOD mice (K.S.G., M.C.J. & R.T.; unpublished results).
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The above results are consistent with IL-2 providing critical signals for the maintenance of
the FoxP3+Treg compartment in general [24, 25], and specifically CD62LHIFoxP3+Treg.
Our findings demonstrate that the temporal shift in the composition of FoxP3+Treg in NOD
mice correlates with the proliferative status of CD62LHI- versus CD62LLO- expressing
FoxP3+Treg. In the islets of NOD mice a >2-fold increase in the frequency of proliferating
cells is detected in CD62LLO (45%) versus CD62LHI (17%) -expressing FoxP3+Treg (Fig.
4A,B). However, the frequency of proliferating CD62LHIFoxP3+Treg is increased 2-fold in
the islets of NOD.B6Idd3 (33%) versus NOD (17%) mice (Fig. 4A,B), resulting in a
significantly increased ratio of dividing CD62LHIFoxP3+Treg to CD62LLOFoxP3+Treg in
NOD.B6Idd3 islets (Fig. 4C). A similar trend was detected in the islets of NOD mice treated
with AAV-Tet-IL-2 and fed doxycycline (Supplementary Fig. 2). Increased proliferation in
NOD.B6Idd3 mice would be expected to promote more efficient maintenance of the
CD62LHIFoxP3+Treg pool compared to NOD mice. Although the frequency of proliferating
CD62LLOFoxP3+Treg was also increased in the islets of NOD.B6Idd3 (55%) versus NOD
(45%) mice, the difference between the two was not as great as that seen between the
respective CD62LHIFoxP3+Treg pools (Fig. 4A,B). This finding suggests that
CD62LHIFoxP3+Treg are more sensitive to changes in the level of IL-2 than
CD62LLOFoxP3+Treg. Elevated IL-2 expression by conventional T cells in NOD.B6Idd3
mice may therefore selectively increase proliferation (Fig. 4) and survival [24] of
suppressor-efficient CD62LHIFoxP3+Treg residing in the islets. IL-2 also has direct effects
on CD62LLOFoxP3+Treg. As noted above, IL-2 converts a significant number of sorted
CD62LLOFoxP3+Treg into CD62LHIFoxP3+Treg in vitro (Fig. 6D), possibly reflecting
down-regulation of the activation status of CD62LLOFoxP3+Treg. Indeed, IL-2 mediates
both positive and negative effects on conventional T cells depending on the activational
status of the cells [28, 47]. Finally, APC may also influence the CD62LHIFoxP3+Treg to
CD62LLOFoxP3+Treg ratio in vivo. The type and activational status of professional APC
can have a marked effect on FoxP3+Treg induction/expansion. Groups have shown that
macrophages and DCs exhibit an increased tolerogenic capacity in NOD.Idd3 versus NOD
mice [48, 49]; the mechanistic basis for this enhanced tolerogenic effect, however, has yet to
be determined.
Recent studies with NOD.Idd3 congenic lines have shown that NOD-derived FoxP3+Treg
exhibit an impaired suppressor function [37, 38]. Our results demonstrate that the limited
suppressor activity reported for NOD FoxP3+Treg is due to an increased number and
frequency of suppressor-deficient CD62LLOFoxP3+Treg, which “dilute out” the suppressor-
competent CD62LHIFoxP3+Treg. The limited suppressor function of sorted NOD or
NOD.B6Idd3 CD62LLOFoxP3+Treg was demonstrated in vitro (Fig. 5D), consistent with an
earlier report [7]. These results, however, differ from work published by Szanya et al. which
demonstrated that CD62LHICD4+CD25+ and CD62LLOCD4+CD25+ T cells from the spleen
of NOD mice differ in suppressor activity only in in vivo, but not in vitro assays [19]. The
level of anti-CD62L Ab-binding and the gating scheme may account for differences in the
frequency of and in turn the in vitro suppressor activity of the pool of CD62LLOFoxP3+Treg
in the respective studies. In addition, Szanya et al. examined splenic-derived
CD62LLOFoxP3+Treg, whereas in this study CD62LLOFoxP3+Treg were prepared from
PLN; “tissue residency” may also influence the suppressor activity of these T cells and
contribute to the disparity between the studies. Reduced TGFβ1 [7] expression relative to
CD62LHIFoxP3+Treg, however, is consistent with a diminished suppressor activity by
CD62LLOFoxP3+Treg. In contrast to NOD mice, the increased frequency of
CD62LHIFoxP3+Treg in the PLN and islets of NOD.B6Idd3 mice efficiently blocks β cell
autoimmunity (Fig. 5B,C). Supporting this model is the marked increase in the ratio of
FoxP3+Treg to T effectors detected in the PLN and islets of NOD.B6Idd3 mice relative to
age-matched NOD female mice (Fig. 5A). In addition, CD4+CD25+ T cells from the PLN of
NOD.B6Idd3 mice proved to be more effective at suppressing the adoptive transfer of
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diabetes relative to NOD CD4+CD25+ T cells (Fig. 5C). One caveat with the latter finding is
that despite similar numbers of activated T effectors (e.g. FoxP3−CD4+CD25+ T cells) in the
transferred NOD and NOD.B6Idd3 CD4+CD25+ T cells, an increased frequency of β cell-
specific pathogenic effector T cells may have limited the efficacy the NOD Treg pool. A
previous study, however, showed that proliferation of transferred diabetogenic CD4+ T cells
was significantly reduced in the PLN of NOD.B6Idd3 versus NOD recipients [38], which is
consistent with NOD.B6Idd3 mice having enhanced suppressor activity. Noteworthy is that
no difference was detected in the in vitro suppressor activity of CD62LHIFoxP3+Treg from
NOD and NOD.B6Idd3 mice (Fig. 4C); in addition similar in vivo suppressor activity was
detected for the respective CD62LHIFoxP3+Treg as determined by co-adoptive transfer
experiments (M.C.J. & R.T.; unpublished data). These observations argue that quantitative
and not qualitative differences in CD62LHIFoxP3+Treg explain the distinct suppressor
activity of the FoxP3+Treg pool detected in NOD and NOD.B6Idd3 mice (Fig. 5B). It is
important to note that the frequency of CD62LHIFoxP3+Treg decreased with age in the islets
of NOD.B6Idd3 albeit to a lesser extent than seen in NOD islets (Fig. 3D). NOD.B6Idd3
mice develop insulitis and diabetes but at a reduced frequency and a delayed onset compared
to NOD mice (Fig. 1). Therefore, in addition to IL-2 other factors contribute to the
homeostasis and function of CD62LHIFoxP3+Treg.
In summary we demonstrate that reduced IL-2 expression impacts FoxP3+Treg in NOD
mice by altering the ratio of CD62LHI to CD62LLO FoxP3+Treg and in turn reducing the
suppressor activity of the FoxP3+Treg compartment. These findings provide further
rationale for the development of IL-2-based immunotherapy as a means to manipulate
FoxP3+Treg for the prevention and suppression of β cell autoimmunity.
MATERIALS & METHODS
Mice
NOD/LtJ and NOD.CB17-Prkdcscid/J (NOD.scid) mice were maintained and bred under
pathogen-free conditions in an American Association for Laboratory-accredited animal
facility. NOD.B6c3D mice, provided by Dr. Ed Leiter (The Jackson Laboratory) were
established by introgression of an ~17 Mb region of the Idd3 interval derived from B6 mice
(NOD.B6Idd3) for 13 backcross generations. The length of the congenic interval was
determined by typing with MIT microsatellite markers and using the MGI posting data from
NCBI Build 37 (Supplementary Table 1). Mice were monitored for diabetes by measuring
urine glucose levels. All procedures were approved by the University of North Carolina
Animal Use and Care Committee.
T cell isolation and culturing conditions
Single cell suspensions were prepared from the thymus, pancreatic lymph nodes (PLN), and
spleen, and filtered with a 70 μM strainer (Fisher Scientific). PBL were obtained via
submandibular puncture using lancets (Golden Rod) and RBC lysed with ACK solution.
Islet infiltrating cells were isolated from purified, hand-picked islets. Briefly, pancreases
were digested with 2.0 mg/ml Collagenase P (Roche) for 20 min at 37°C, and islets purified
on a Ficoll (Sigma-Aldrich) gradient. Lymphocytes infiltrating the islets were harvested by
dissociating the islets using enzyme-free cell dissociation solution (Sigma-Aldrich).
Naïve CD4+ T cells were isolated from splenocytes using a bead-based naïve CD4 T cell kit
(Miltenyi Biotec). Briefly, total lymphocytes were incubated with a biotin-labeled Ab
cocktail that selectively enriches for CD4+ T cells but depletes CD4+CD25+ cells. Enriched
CD4+CD25− T cells were then incubated with CD62L-conjugated micro-beads and isolated
using a magnetic column.
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For general T cell cultures, 2×105 cells were resuspended in complete RPMI 1640 medium
(Gibco) containing 10% heat-inactivated FBS, 100 U/ml penicillin/streptomycin (Gibco),
and 50 uM 2-ME (Sigma-Aldrich). T cells were stimulated in 96-well plates coated with
varying concentrations of purified anti-CD3 Ab (2C11, eBioscience) and soluble,
functional-grade anti-CD28 Ab at 2 ug/ml (37.51, eBioscience). In some experiments
supernatants were collected, diluted 1:3 in 1% BSA in PBS, and IL-2 secretion measured 24
h post stimulation. An anti-IL-2 Ab set (eBioscience) was used at 2 ug/ml on a high-binding
ELISA plate (Costar).
FACS
Total cells from the respective tissues were stained with a variety of
fluorochromeconjugated monoclonal Ab (mAb) including: anti-CD3 (2C11), anti-CD4
(L3T4), anti-CD8 (Ly-2), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-CD62L (MEL14),
and anti-FoxP3 (FJK.16 kit) (eBioscience). Fc receptors were blocked with a 1/200 dilution
of rat Ig prior to staining. Intracellular Ki67 (B56; BD Biosciences) staining was done using
cytofix/cytoperm reagents (BD Biosciences) according to manufacturer’s specifications.
Data were acquired on a Cyan flow cytometer (DakoCytomation), and analyzed using
Summit software (DakoCytomation). In addition CD4+CD25+ T cells (CD62LLO or
CD62LHI) were sorted by a MoFlo high-speed sorter (DakoCytomation).
Intracellular cytokine staining was preformed on single cell suspensions from PLN or islet-
infiltrating cells as previously described [50]. Briefly, lymphocytes were stimulated with 10
ng/ml PMA (Sigma-Aldrich) and 150 ng/ml ionomycin (Sigma-Aldrich) in complete RPMI
1640 medium for 6 h at 37°C; 10 ug/ml of Brefeldin A (Sigma-Aldrich) was added for the
final 4 h of incubation. Cells were stained for surface molecules, fixed and permeabilized
with cytokfix/cytoperm reagents (BD Biosciences), and stained for intracellular IFN-γ
(XMG1.2) (eBioscience).
In vitro suppression assay
Different ratios of FACS-sorted CD4+CD25+CD62LLO/HI T cells were cultured with cell-
trace violet (Invitrogen) labeled naïve 5×104 CD4+ T cells, 2 ug/ml anti-CD28, and 2 μg/ml
anti-CD3 Ab in 96-well round bottom plates (Costar) for 3 d. Proliferation was assessed in
triplicate by FACS analysis as the total percentage of labeled CD4+Thy1.2+ naïve cells
undergoing at least one round of division.
Cell adoptive transfers
Diabetogenic NOD splenocytes (2.5×106) were suspended in PBS and injected i.p. into 8
wk-old NOD.scid male mice alone or in combination with FACS sorted CD4+CD25+ T cells
(1×105) isolated from the PLN of NOD or NOD.B6Idd3 mice. Mice were monitored bi-
weekly post-transfer for diabetes.
Construction of and treatment with adeno-associated virus encoding NOD IL-2
Using the forward primer 5′-gaagcttcaggcatgtacagcatgcagctc-3′ that includes a HindIII
restriction site and the reverse primer 5′-gtcgactagttattgagggcttgttgagat-3′ that contains an
EcoRV restriction site, the Il2 gene was PCR amplified with PFU Turbo (Promega) from
mRNA (Qiagen) of ConA (Sigma-Aldrich) stimulated NOD lymphocytes. Amplicons were
subcloned into the topo-TA vector (Invitrogen) and sequenced. Full-length cDNA encoding
Il2 was subcloned into an adeno-associated virus (AAV)-Tet-on vector plasmid (kindly
provided by Dr. Sihong Song) using SalI and EcoRV sites. Transgene expression was
verified by measuring via ELISA IL-2 secretion by HEK 293 cells transfected with AAV-
Tet-on-IL-2 plasmid DNA.
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AAV virus production was previously described [51]. Briefly, packaged AAV serotype 1
(AAV1) virus was prepared by transfecting 293 cells via calcium phosphate with the adeno
helper encoding plasmid (pXX6-80), AAV1 encoding plasmid (pXR-1), and the Tet-on-IL-2
constructs (described above). Nuclear fractions were harvested and virus purified with an
iodixonal (Sigma-Aldrich) gradient. The virus containing fractions and titer were determined
by Southern dot blot.
NOD female mice were vaccinated with 5×1010 viral particles of AAV-Tet-on-IL-2 virus
serotype 1 (AAV-Tet-IL-2) in contra-lateral, hind limb muscles using an insulin syringe.
After injection, mice were fed chow containing 200 mg/kg doxycycline (BioServ) for 2 wks.
Insulitis scoring
Pancreases were harvested and fixed with formalin for 24 h. Serial sections 90 um apart
were prepared and stained with H&E. More than 100 islets were scored per group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NOD.B6Idd3 female mice exhibit a reduced frequency of diabetes and insulitis
compared to NOD female mice
(A) Female NOD (open square, n=20) and NOD.B6Idd3 (black square, n=19) were
monitored for diabetes incidence. ***, p<0.001 (Kaplan-Meier Log Rank Test). (B) The
frequency of insulitis in the pancreas of 16 wk old NOD (n=7) and NOD.B6Idd3 (n=6)
female mice was determined via H&E staining. * p<0.05, *** p<0.001; NOD versus
NOD.B6Idd3 for a given type of insulitis (Chi Square).
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Figure 2. NOD.B6Idd3 mice have an increased frequency of peripheral FoxP3+Treg compared
to age-matched NOD mice
(A) Representative FACS plots of NOD and NOD.B6Idd3 PLN at 16 wks of age staining for
CD3+CD4+ T cells (left column) used to gate CD25+FoxP3+ T cells (right columns) with
the average percentage of the indicated populations shown to the right of each gate. The (B)
frequency and (C) absolute number of CD3+CD4+CD25+FoxP3+ T cells in the thymus,
spleen, PLN and islets were measured in female NOD (n=8-15/age group) and NOD.B6Idd3
mice (n=7-16/age group) at 4, 10 and 16 wks of age. The absolute number in each respective
tissue was determined by multiplying the total number of counted cells by the percentage of
T cells determined by FACS. *, p<0.05; **, p<0.01; ***, p<0.001; NOD.B6Idd3 versus
NOD for a given tissue (2-way ANOVA, data are mean ±SEM).
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Figure 3. A temporal shift in CD62LHI- versus CD62LLO-expressing FoxP3+Treg is detected in
NOD but not NOD.B6Idd3 female mice
(A) Representative FACS staining profile of CD62L expression on gated
CD3+CD4+CD25+FoxP3+ T cells in the PLN of 16 wk-old NOD and NOD.B6Idd3 mice.
The (B, D) frequency and (C, E) number of CD62LHI- and CD62LLO-expressing
CD3+CD4+CD25+FoxP3+ T cells in the (B, C) PLN and (B, C) islets of 4, 10 and/or 16
wk-old NOD (n=7-10/age group) and NOD.B6Idd3 (n=8-10/age group) female mice. *,
p<0.05; **, p<0.01; ***, p<0.001; NOD.B6Idd3 versus NOD for a given tissue (2-way
ANOVA, data are ±SEM).
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Figure 4. Proliferation of CD62LHIFoxP3+Treg is increased in the islets of NOD.B6Idd3 versus
NOD female mice
(A) Representative FACS plots for the gating scheme used to assess the frequency of islet
infiltrating Ki67-staining CD62LHI versus CD62LLO in CD4+CD25+FoxP3+ T cells of 12
wk-old NOD and NOD.B6Idd3 female mice. (B) Average percent and (B) the ratio of Ki67-
staining CD62LHICD4+CD25+FoxP3+ and CD62LLOCD4+CD25+FoxP3+ T cells from the
islets of 12 wk-old NOD (n=5) and NOD.B6Idd3 (n=5) female mice. *, p<0.05; **, p<0.01;
***, p<0.001 (2-way ANOVA, data are + SEM).
Goudy et al. Page 16













Figure 5. The FoxP3+Treg pool in 16 wk-old NOD.B6Idd3 versus NOD female mice exhibits
increased suppressor activity
(A) The ratio of CD62LHI-expressing CD3+CD4+CD25+FoxP3+ T cells to CD3+CD4+ T
cells expressing intracellular IFNγ (e.g. type 1 T effectors (Teff)) was determined in the
islets and PLN of 16 wk-old NOD (n=9 and n=6, respectively) and NOD.B6Idd3 (n=10 and
n=6, respectively) female mice via FACS. Each data point represents an individual mouse,
horizontal bar represents the mean. **, p<0.01; ***, p<0.001; NOD.B6Idd3 versus NOD
(Student’s t Test). (B) Ki67 staining for T cell proliferation of CD3+ T cells in the islets of
16 wk-old NOD.B6Idd3 (n=6) versus NOD (n=5) female mice; ***, p<0.001 (Students t
Test). (C) CD4+CD25+ T cells sorted from pooled PLN of 16 wk-old NOD or NOD.B6Idd3
female mice were transferred with diabetogenic NOD splenocytes into NOD.scid mice (n=5
per group) and diabetes monitored; as a control diabetogenic splenocytes alone were
transferred into NOD.scid recipients; **, p<0.001, NOD.B6Idd3 versus NOD CD4+CD25+
T cells (Kaplan-Meier Log Rank Test). (D) The in vitro suppressor activity was compared
between CD62LHI- and CD62LLO-expressing CD4+CD25+ T cells sorted from the PLN of 16
wk-old NOD and NOD.B6Idd3 female mice. Suppressor activity was determined by
measuring via FACS proliferation of celltrace violet dye labeled CD4+CD25− responder T
cells stimulated with anti-CD3 plus - CD28 Ab, and cultured with varying numbers of
CD62LHI- or CD62LLO-expressing CD4+CD25+ T cells; data are the average percent of
proliferation from 2 wells±SEM. **, p<0.01; *, p<0.05; CD62LHI versus CD62LLO in NOD
and NOD.B6Idd3 (2-way ANOVA, ). Data are representative of three independent
experiments.
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Figure 6. Increased IL-2 induces an elevated frequency of CD62LHIFoxP3+Treg in vivo and in
vitro
(A) A representative FACS plot of the frequency of CD3+CD4+ gated T cells expressing
CD25 and FoxP3 in PBL prepared from NOD female mice left untreated (Untx; n=5) or
injected at 10 wks of age with AAV-Tet-IL-2 and given doxycycline containing chow for 2
wk (induced; n=5) or not (uninduced; n=4) 3 wks-post induction (average percentages per
group are inlayed in the dot plots). Similarly the frequency of (B)
CD3+CD4+CD25+FoxP3+ T cells in the spleen, popliteal lymph nodes (Pop) and PLN, and
(C) CD62LHI- expressing CD3+CD4+CD25+FoxP3+ T cells in the PLN were determined
via flow cytometry in the respective groups of NOD mice. (C) Each data point represents an
individual mouse, horizontal bars represent the mean. ***, p<0.001 (2-way ANOVA, data
are±SEM). (D) CD62L expression after culturing for 48 h sorted CD62LHI or CD62LLO
CD3+CD4+CD25+ T cells in the presence or absence of 20 ng/ml of IL-2 . ***, p<0.001,
CD62LLO (−IL-2) versus CD62LLO (+IL-2) (Student’s t Test, data are ±SEM).
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